Glucocorticoid-induced osteoporosis: from clinical trials to clinical practice

Glucocorticoid-induced osteoporosis (GIOP) is the most common form of secondary osteoporosis. To date, six large randomized controlled clinical trials on the efficacy of pharmaceutical treatment in GIOP have been conducted. All of these studies have focused predominately on bone mineral density outc...

Full description

Saved in:
Bibliographic Details
Published in:Therapeutic Advances in Musculoskeletal Disease 2019, Vol.11, p.1759720X19876468-1759720X19876468
Main Authors: Adami, Giovanni, Rahn, Elizabeth J, Saag, Kenneth G
Format: Article
Language:English
Subjects:
Clinical trials
Fractures
Osteoporosis
Review
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Glucocorticoid-induced osteoporosis (GIOP) is the most common form of secondary osteoporosis. To date, six large randomized controlled clinical trials on the efficacy of pharmaceutical treatment in GIOP have been conducted. All of these studies have focused predominately on bone mineral density outcomes, and none of them have been statistically powered to address fracture endpoints. The purpose of this review is to highlight differences in the design and results within these large randomized GIOP clinical trials, and how these differences might affect clinical decisions. Differences between studies in trial design, populations studied, and variable efficacy impact the comparability and generalizability of these findings, and ultimately should affect practitioners’ behavior. We review the clinical trials that provide the best quality evidence on comparative efficacy and safety of GIOP treatments. We also propose suggestions on the design of future GIOP clinical trials with attention to improved generalizability, and, ideally, study designs that might achieve fracture outcomes.
ISSN:1759-720X
1759-7218
DOI:10.1177/1759720X19876468